NCT00445484 · REGISTRY CONDITION SEARCH

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2015-08-24

RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

6B Antibody Response to Prevnar Vaccine in Peripheral Blood

→

outcome · POSTED

14F Antibody Response to Prevnar Vaccine in Peripheral Blood

→

outcome · POSTED

19F Antibody Response to Prevnar Vaccine in Peripheral Blood

→

outcome · POSTED

23F Antibody Response to Prevnar Vaccine in Peripheral Blood

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Diagnosis of multiple myeloma (MM) meeting all of the following criteria: * Relapsed or refractory disease * Previously received ≥ 2 courses of antimyeloma treatment * Measurable levels of myeloma paraprotein in serum (\> 0.5 g/dL) or urine (\> 0.2 g/24-hour urine collection) OR serum-free light-chain disease PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 75,000/mm\^3 * Creatinine ≤ 2.5 mg/dL * Bilirubin ≤ 2.0 mg/dL * AST and ALT ≤ 3 times upper limit of normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use 2 methods of highly effective contraception ≥ 4 weeks before, during, and for 4 weeks after completion of study therapy * No other malignancy within the past 5 years except treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast * No serious medical condition, laboratory abnormality, or psychiatric illness that would preclude study treatment or put patient at unacceptable risk * No known hypersensitivity to thalidomide or lenalidomide * No development of erythema nodosum in the presence of a reaction characterized by a desquamating rash while taking thalidomide or similar drugs * No known hypersensitivity to any component of the pneumococcal polyvalent vaccine, including diphtheria toxin or CRM 197 * No known HIV positivity * No infectious hepatitis type A, B, or C PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No more than 3 prior treatment regimens for MM * More than 6 months since prior lenalidomide * More than 28 days since prior experimental drug or therapy * More than 1 month since prior systemic antimyeloma therapy * More than 1 month since prior and no concurrent systemic corticosteroids * No other concurrent anticancer agents or treatments or investigational agents * No concurrent thalidomide * No concurrent radiotherapy * No other concurrent immune therapy or immunomodulatory agents
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
intervention Names
Biological: pneumococcal polyvalent vaccine
Drug: lenalidomide
label
Group 1
type
EXPERIMENTAL
description
Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
intervention Names
Biological: pneumococcal polyvalent vaccine
Drug: lenalidomide
label
Group 2
type
EXPERIMENTAL

interventions

arm Group Labels
Group 1
Group 2
description
Given intramuscularly
name
pneumococcal polyvalent vaccine
type
BIOLOGICAL
arm Group Labels
Group 1
Group 2
description
Given orally
name
lenalidomide
type
DRUG

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 22
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Serum IgG levels against the PVC serotype were measured by ELISA
measure
6B Antibody Response to Prevnar Vaccine in Peripheral Blood
time Frame
basline and 8 weeks after second vaccination
description
Serum IgG levels against the PVC serotype were measured by ELISA
measure
14F Antibody Response to Prevnar Vaccine in Peripheral Blood
time Frame
basline and 8 weeks after second vaccination
description
Serum IgG levels against the PVC serotype were measured by ELISA
measure
19F Antibody Response to Prevnar Vaccine in Peripheral Blood
time Frame
basline and 8 weeks after second vaccination
description
Serum IgG levels against the PVC serotype were measured by ELISA
measure
23F Antibody Response to Prevnar Vaccine in Peripheral Blood
time Frame
basline and 8 weeks after second vaccination

Full study description

brief Summary: RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.
detailed Description: OBJECTIVES: Primary * Determine whether lenalidomide can augment the efficacy of pneumococcal polyvalent vaccine as it correlates with lenalidomide-induced antitumor efficacy in patients with relapsed or refractory multiple myeloma. Secondary * Determine the antibody responses to pneumococcal serotypes in patients treated with this regimen. * Determine T-cell responses to the carrier protein CRM 197 in patients treated with this regimen. * Determine the ability of lenalidomide to augment in vivo immune responsiveness as measured by cutaneous delayed-type hypersensitivity (DTH) reactions to Candida and tetanus in these patients. * Determine the ability of lenalidomide to prime and/or boost systemic vaccine responses in both peripheral blood lymphocytes and marrow lymphocytes in these patients. OUTLINE: Patients are assigned to 1 of 2 treatment groups. * Group 1: Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine). * Group 2: Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine). After completion of study treatment, patients are followed at 30 days. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Source references

references

citation
Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, Borrello I. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012 Mar 1;18(5):1426-34. doi: 10.1158/1078-0432.CCR-11-1221. Epub 2012 Jan 12.
pmid
22241792
type
RESULT

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-0efe494989f3b027febf
requested nct id
NCT00445484
primary nct id
NCT00445484
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
06f22d9c68e0a3deed9d69d3570753f79105e67ae0bbdd459257d96955ee0968
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-0efe494989f3b027febf
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00445484
occurrences
context exact
NCT00445484
end
11
exact text
NCT00445484
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/672/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
f1573b16d06f61e2752f96137bef5296e56bb94574465ee66672e6cc17ab979f
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice